NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more
Market Cap & Net Worth: NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
NewAmsterdam Pharma Company N.V. Ordinary Shares (NASDAQ:NAMS) has a market capitalization of $3.38 Billion ($3.38 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5180 globally and #3097 in its home market, demonstrating a -0.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NewAmsterdam Pharma Company N.V. Ordinary Shares's stock price $29.79 by its total outstanding shares 113390804 (113.39 Million).
NewAmsterdam Pharma Company N.V. Ordinary Shares Market Cap History: 2021 to 2026
NewAmsterdam Pharma Company N.V. Ordinary Shares's market capitalization history from 2021 to 2026. Data shows growth from $1.11 Billion to $3.38 Billion (22.01% CAGR).
Index Memberships
NewAmsterdam Pharma Company N.V. Ordinary Shares is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.08% | #134 of 976 |
|
NASDAQ Composite
IXIC
|
$33.26 Trillion | 0.01% | #611 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.12% | #84 of 263 |
Weight: NewAmsterdam Pharma Company N.V. Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NewAmsterdam Pharma Company N.V. Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NewAmsterdam Pharma Company N.V. Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
64.46x
NewAmsterdam Pharma Company N.V. Ordinary Shares's market cap is 64.46 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.24 Billion | $102.69 Million | -$22.63 Million | 12.04x | N/A |
| 2023 | $1.27 Billion | $14.09 Million | -$176.94 Million | 89.89x | N/A |
| 2024 | $2.94 Billion | $45.56 Million | -$241.60 Million | 64.46x | N/A |
Competitor Companies of NAMS by Market Capitalization
Companies near NewAmsterdam Pharma Company N.V. Ordinary Shares in the global market cap rankings as of March 18, 2026.
Key companies related to NewAmsterdam Pharma Company N.V. Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NewAmsterdam Pharma Company N.V. Ordinary Shares Historical Marketcap From 2021 to 2026
Between 2021 and today, NewAmsterdam Pharma Company N.V. Ordinary Shares's market cap moved from $1.11 Billion to $ 3.38 Billion, with a yearly change of 22.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.38 Billion | -15.08% |
| 2025 | $3.98 Billion | +35.44% |
| 2024 | $2.94 Billion | +131.87% |
| 2023 | $1.27 Billion | +2.48% |
| 2022 | $1.24 Billion | +11.79% |
| 2021 | $1.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of NewAmsterdam Pharma Company N.V. Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.38 Billion USD |
| MoneyControl | $3.38 Billion USD |
| MarketWatch | $3.38 Billion USD |
| marketcap.company | $3.38 Billion USD |
| Reuters | $3.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.